TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...

ALTA3263 is an oral KRAS-selective inhibitor specifically designed to potently inhibit the KRAS “ON” (active) state of greater than 90% of all KRAS mutations and to provide complete target ...

GTPase KRAS G12D mutant and/or G12V mutant inhibitors potentially useful for the treatment of cancer have been detailed in a Quanta Therapeutics Inc.

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

QTX3544 is an oral, G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor currently being evaluated in a Phase 1 clinical trial in patients with KRASG12V mutations. The mitogen-activated ...

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

Silexion Therapeutics Corp. has announced an expanded development plan for its next-generation siRNA candidate SIL-204. The new dual-route strategy will integrate intratumoral and systemic ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...

When one of the proteins in the pathway is mutationally activated, it can drive tumor development and growth. RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in ...